STALICLA
Company Details
Status: Private
Employees: 11-50
Location:
Campus Biotech Innovation Park, Av. de Secheron 15, 1202
Type:
sample
sample
Technology:
sample
sample
sample
About: STALICLA SA is a Swiss clinical-stage biopharmaceutical company pioneering Neuro Precision Medicine in neurodevelopmental and neuropsychiatric disorders. With state-of-the-art technology platforms and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatments.
Neurodevelopmental Disorders: To propel neurodevelopmental research, STALICLA have identified patient subgroups and their matching candidate drugs within Autism Spectrum Disorder using its trailblazing, multi-omics DEPI platform. STALICLA is currently preparing Phase 2 trials for STP1, STALICLA's first patient subgroup-matched precision treatment.
Substance Use Disorder research: STALICLA is working in partnership with the National Institute of Drug Abuse (NIDA) to advance Phase 3 clinical trials for the most clinically advanced drug candidate for cocaine abuse disorder, STP7.
STALICLA is now raising series C funding to advance both verticals. For more information visit: https://stalicla.com.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
STALICLA | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.